192 results
8-K
EX-99.1
MBRX
Moleculin Biotech Inc
15 May 24
Regulation FD Disclosure
8:38am
Act of 1933, Section 21E of the Securities Exchange Act of 1934 and the Private Securities Litigation Reform Act of 1995, which involve risks
8-K/A
EX-99.1
MBRX
Moleculin Biotech Inc
13 May 24
Moleculin Reports First Quarter 2024 Financial Results and Provides Corporate Update
10:53am
, Section 21E of the Securities Exchange Act of 1934 and the Private Securities Litigation Reform Act of 1995, which involve risks and uncertainties. Forward
8-K
EX-99.1
MBRX
Moleculin Biotech Inc
13 May 24
Moleculin Reports First Quarter 2024 Financial Results and Provides Corporate Update
7:30am
, Section 21E of the Securities Exchange Act of 1934 and the Private Securities Litigation Reform Act of 1995, which involve risks and uncertainties. Forward
8-K
EX-99.1
MBRX
Moleculin Biotech Inc
9 May 24
Moleculin Announces U.S. Patent Issue Notification for Lipid-Based Delivery Technology for Annamycin
8:30am
, Section 21E of the Securities Exchange Act of 1934 and the Private Securities Litigation Reform Act of 1995, which involve risks and uncertainties
8-K
EX-99.1
MBRX
Moleculin Biotech Inc
7 May 24
Moleculin Reports Higher AML Complete Remission (CR) Rates and Significant Durability with Additional Interim Subject Data
8:55am
the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934 and the Private Securities Litigation Reform Act
8-K
EX-99.1
vvs5hjju10jx vk
2 May 24
Regulation FD Disclosure
9:00am
8-K
EX-99.1
6xzy9s4xb
18 Apr 24
Regulation FD Disclosure
8:30am
8-K
EX-99.1
agybeht10czmfis
10 Apr 24
Moleculin Announces Presentation of Positive Data Demonstrating High Anti-Cancer Activity of Annamycin and Non-Cardiotoxic Properties
8:30am
8-K
EX-99.1
4gleavo28fg0w0a1 g46
27 Mar 24
Moleculin Announces U.S. Patent Issue Notification for Annamycin Targeting Unmet Need in AML
9:05am
8-K
EX-99.1
ksey2k
25 Mar 24
Moleculin Announces Positive Interim Data in Annamycin MB-106 Phase 1B/2 AML Trial
7:30am
8-K
EX-99.1
4hvv1q 9cd
22 Mar 24
Moleculin Reports Full Year 2023 Financial Results
4:08pm
8-K
EX-99.1
35re1yjygyncm 0s9o
19 Mar 24
Moleculin Announces Reverse Stock Split
4:31pm
424B3
y6r 6l4rp
16 Feb 24
Prospectus supplement
5:19pm
8-K
EX-99.1
t4cji5hqs1m rb
24 Jan 24
Regulation FD Disclosure
8:50am
8-K
EX-99.1
03he44o
21 Dec 23
Moleculin Announces Pricing of $4.5 Million Registered Direct Offering and Concurrent Private Placement Priced At-the-Market
5:17pm
8-K
EX-10.1
x72eojlw2lckq tv
21 Dec 23
Moleculin Announces Pricing of $4.5 Million Registered Direct Offering and Concurrent Private Placement Priced At-the-Market
5:17pm
8-K
EX-99.1
7uvtct1kv7b9lvcpe1q
11 Dec 23
Moleculin Presents Positive Interim Data from Phase 1B/2 Clinical Trial in AML at Meeting with KOL’s in Conjunction with ASH Annual Meeting
8:50am